Clinical trial NCT03720431: TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer
Official title: A Phase 1b, Open-Label, Safety and Tolerability Study of TTAC-0001 in Combination With Pembrolizumab in Patients With Metastatic Triple-Negative Breast Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Triple Negative Breast Cancer
Lead sponsor: PharmAbcine
Sponsor class: INDUSTRY
First posted: 2018-10-25
Enrollment: 11
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This is a phase 1b, open-Label clinical trial to determine the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of TTAC-0001 administered in combination with pembrolizumab in patients with metastatic triple-negative breast cancer.


Eligibility criteria: Inclusion Criteria:

1. Female and male patients ≥18 years old
2. Histologically proven metastatic breast carcinoma with triple negative receptor status (Estrogen receptor, Progesterone receptor and human epidermal growth factor receptor 2 \[HER2\] negative) by IHC and Fluorescence in situ hybridization (FISH) according to ASCO-CAP guideline3.
3. At least one confirmed measurable lesion by RECIST 1.1 criteria
4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1
5. A person who satisfies the following criteria in hematologic, renal, and hepatic function tests performed within 7 days prior to screening:

(1) Hematologic tests

* Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
* Platelets ≥ 100 x 109/L
* Haemoglobin ≥ 9.0 g/dL (2) Blood coagulation tests
* Prothrombin time (PT) ≤ 1.5 x Upper limit of normal (UNL)
* Activated partial thromboplastin Time (aPTT) ≤ 1.5 x UNL (3) Hepatic function tests
* Total bilirubin ≤ 1.5 x UNL
* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 2.5 x ULN (≤ 5 x ULN in case of liver metastasis) (4) Renal function test
* ≤1.5 × ULN or creatinine clearance (CrCl) ≥30 mL/min for patient with creatinine levels \>1.5 × institutional ULN 6) At least 12 weeks of expected life expectancy 7) The patient (or legally acceptable representative if applicable) is able and willing to provide written informed consent for the trial.

Exclusion Criteria:

1. Has a known additional malignancy that is progressing or has required active treatment within the past 2 years. (Note: Patients with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) controlled by curative therapy are not excluded)
2. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment
3. Has a history of (non-infectious) pneumonitis/interstitial lung diseases that required steroids or current pneumonitis/interstitial lung disease.
4. Has an active infection requiring systemic therapy
5. Uncontrolled hypertension (systolic blood pressure \[SBP\]\> 150 or diastolic blood pressure \[DBP\]\> 90 mmHg)
6. Uncontrolled seizures
7. Class III or IV heart failure by New York Heart Association (NYHA) classification
8. Has oxygen-dependent chronic disease
9. Active psychiatric disorder (schizophrenia, major depressive disorder, bipolar disorder etc.). Treated depression with ongoing antidepressant medication is not an exclusion
10. History of abdominal fistula or gastrointestinal perforation within 6 months prior to start of study drug
11. History of serious gastrointestinal haemorrhage within 6 months prior to start of study drug
12. History of severe arterial thromboembolic event within 12 months of start of study drug
13. Serious grade 4 venous thromboembolic event including pulmonary embolism
14. History of hypertensive crisis or hypertensive encephalopathy
15. History of posterior reversible encephalopathy syndrome
16. Planned surgery within 4 weeks post last dose
17. Moderate to severe proteinuria
18. Requiring therapeutic anticoagulation with warfarin at baseline
19. Not recovered below National Cancer Institute -Common Terminology Criteria for Adverse Events (NCI-CTCAE) grade 1 or baseline from AEs due to previous therapy
20. Treatment with systemic chemotherapy, hormonal therapy, immunotherapy or biologic therapy within 2 weeks prior to the baseline visit
21. Has received prior radiotherapy within 2 weeks of start of study treatment.
22. Undergone major surgery requiring general anaesthesia or a respiratory assistance device within 4 weeks prior to the baseline visit
23. Treated with other investigational drugs within 4 weeks prior to the baseline visit for this study
24. Female who is pregnant\* or lactating and of childbearing potential who does not agree to a reliable and adequate method of contraception
25. A known history of severe drug hypersensitivity or hypersensitivity to a therapy similar to the study drugs
26. Unable to participate in the trial according to the investigator's decision.
27. Previous therapy with vascular endothelial growth factor (VEGF)-targeted agents including (but not limited to) bevacizumab
28. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137) and was discontinued from that treatment due to a Grade 3 or higher irAE

Primary outcomes:
measure: Dose limiting toxicities
timeFrame: During the first cycle (every cycle is 21 days) of treatment
measure: Adverse events
timeFrame: From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
measure: Immunogenicity
timeFrame: From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
Secondary outcomes:
measure: Overall response rate
timeFrame: At every 2nd cycles until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years (every cycle is 21 days)]
measure: Disease control rate
timeFrame: At every 2nd cycles until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years (every cycle is 21 days)
measure: Progression free survival
timeFrame: From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
measure: Overall survival
timeFrame: From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
Other outcomes:
measure: Pharmacokinetic parameters - Cmax
timeFrame: From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
measure: Pharmacokinetic parameters - Cmin
timeFrame: From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
measure: Pharmacokinetic parameters - AUC0-t
timeFrame: From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
measure: Pharmacokinetic parameters - Tmax
timeFrame: From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
measure: Pharmacokinetic parameters - CL
timeFrame: FFrom date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
measure: Pharmacokinetic parameters - Vd
timeFrame: From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
measure: Pharmacokinetic parameters - Ke
timeFrame: From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
measure: Pharmacokinetic parameters - T½
timeFrame: From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
measure: Change in concentration of serum angiogenic factor or receptor
timeFrame: From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
measure: PD-L1, VEGFR-2 expression level
timeFrame: From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
Locations:
city: Liverpool
country: Australia
facility: Liverpool Hospital
state: New South Wales
city: Nedlands
country: Australia
facility: Hollywood Private Hospital
state: Western Australia
Study officials:
References: